Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Beverly L Davidson

Showing results (171-180 of 187) with videos related to

Pageof 19
Sort By:
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 20, 2007
Timing of therapeutic intervention determines functional and survival outcomes in a mouse model of late infantile batten diseaseMario A Cabrera-Salazar, Eric M Roskelley, Jie Bu, et al.
ACS Nano|April 4, 2025
Lipid Nanoparticles for <i>In Vivo</i> Lung Delivery of CRISPR-Cas9 Ribonucleoproteins Allow Gene Editing of Clinical TargetsRebecca M Haley, Marshall S Padilla, Rakan D El-Mayta, et al.
Molecular Genetics and Metabolism|December 31, 2023
A novel iPSC model reveals selective vulnerability of neurons in multiple sulfatase deficiencyVi Pham, Livia Sertori Finoti, Margaret M Cassidy, et al.
Nature Communications|May 6, 2023
Mapping PTBP2 binding in human brain identifies SYNGAP1 as a target for therapeutic splice switchingJennine M Dawicki-McKenna, Alex J Felix, Elisa A Waxman, et al.
Nature Communications|June 25, 2025
AAV-based delivery of RNAi targeting ataxin-2 improves survival and pathology in TDP-43 miceDefne A Amado, Ashley B Robbins, Katherine R Whiteman, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|February 3, 2006
Intracranial delivery of CLN2 reduces brain pathology in a mouse model of classical late infantile neuronal ceroid lipofuscinosisMarco A Passini, James C Dodge, Jie Bu, et al.
American Journal of Human Genetics|April 2, 2026
Implications of the FDA's new plausible mechanism framework for the development of a personalized in vivo prime editing platformEmily R Feierman, Madelynn N Whittaker, Aidan Quigley, et al.
Human Molecular Genetics|July 23, 2021
Immortalized striatal precursor neurons from Huntington's disease patient-derived iPS cells as a platform for target identification and screening for experimental therapeuticsSergey S Akimov, Mali Jiang, Amanda J Kedaigle, et al.
Molecular Psychiatry|July 14, 2026
Translatable electrophysiological and behavioral abnormalities in a humanized model of SYNGAP1-disorderAlex J Felix, Brandon L Brown, Nicolas Marotta, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 19, 2022
Gene-based therapeutics for rare genetic neurodevelopmental psychiatric disordersBeverly L Davidson, Guangping Gao, Elizabeth Berry-Kravis, et al.
Pageof 19

Showing results (171-180 of 187) with videos related to

Sort By:
Pageof 19
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 20, 2007
Timing of therapeutic intervention determines functional and survival outcomes in a mouse model of late infantile batten diseaseMario A Cabrera-Salazar, Eric M Roskelley, Jie Bu, et al.
ACS Nano|April 4, 2025
Lipid Nanoparticles for <i>In Vivo</i> Lung Delivery of CRISPR-Cas9 Ribonucleoproteins Allow Gene Editing of Clinical TargetsRebecca M Haley, Marshall S Padilla, Rakan D El-Mayta, et al.
Molecular Genetics and Metabolism|December 31, 2023
A novel iPSC model reveals selective vulnerability of neurons in multiple sulfatase deficiencyVi Pham, Livia Sertori Finoti, Margaret M Cassidy, et al.
Nature Communications|May 6, 2023
Mapping PTBP2 binding in human brain identifies SYNGAP1 as a target for therapeutic splice switchingJennine M Dawicki-McKenna, Alex J Felix, Elisa A Waxman, et al.
Nature Communications|June 25, 2025
AAV-based delivery of RNAi targeting ataxin-2 improves survival and pathology in TDP-43 miceDefne A Amado, Ashley B Robbins, Katherine R Whiteman, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|February 3, 2006
Intracranial delivery of CLN2 reduces brain pathology in a mouse model of classical late infantile neuronal ceroid lipofuscinosisMarco A Passini, James C Dodge, Jie Bu, et al.
American Journal of Human Genetics|April 2, 2026
Implications of the FDA's new plausible mechanism framework for the development of a personalized in vivo prime editing platformEmily R Feierman, Madelynn N Whittaker, Aidan Quigley, et al.
Human Molecular Genetics|July 23, 2021
Immortalized striatal precursor neurons from Huntington's disease patient-derived iPS cells as a platform for target identification and screening for experimental therapeuticsSergey S Akimov, Mali Jiang, Amanda J Kedaigle, et al.
Molecular Psychiatry|July 14, 2026
Translatable electrophysiological and behavioral abnormalities in a humanized model of SYNGAP1-disorderAlex J Felix, Brandon L Brown, Nicolas Marotta, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 19, 2022
Gene-based therapeutics for rare genetic neurodevelopmental psychiatric disordersBeverly L Davidson, Guangping Gao, Elizabeth Berry-Kravis, et al.
Pageof 19